- Beijing Yuanxin Technology raised $465 million in a Series E round to support its online/offline healthcare operations.
- Shanghai Microport Cardioflow Medtech, a spinout from China medical device maker Microport, completed a $324 million IPO in Hong Kong.
- Hangzhou Zhongmei Huadong Pharma formed a $180 million collaboration with Provention Bio of New Jersey to develop a bispecific drug targeting B cell surface proteins CD32B and CD79B in China.
For further details see:
Week In Review: Yuanxin Raises $465 Million For Online Healthcare Company Miaoshou Doctor